OSE Pharma SA, of Paris, said it initiated in the U.S. its phase III trial, Atalante 1, evaluating Tedopi, an off-the-shelf immunotherapy, for advanced non-small-cell lung cancer (NSCLC). The study, which is comparing Tedopi to standard chemotherapies in positive HLA-A2 patients with stage IIIb or IV NSCLC, started in Europe in early 2016. The trial will include a total of 500 patients and results are expected in 2018.